Switching as only temporal solution for patients with antipsychotic-associated diabetes: further observations.
Margetić
Branimir
B
Aukst Margetić
Branka
B
D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D003024:Clozapine / Q000008:administration & dosage / Q000009:adverse effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy; D003987:Dibenzothiazepines / Q000008:administration & dosage / Q000009:adverse effects; D003927:Diet, Diabetic; D004359:Drug Therapy, Combination; D005260:Female; D005476:Fluphenazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008297:Male; D008403:Mass Screening; D000069348:Quetiapine Fumarate; D012307:Risk Factors; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy*
D014150:Antipsychotic Agents; D001786:Blood Glucose; D003024:Clozapine; D003987:Dibenzothiazepines; D005476:Fluphenazine; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000069348:Quetiapine Fumarate; C011825:fluphenazine depot